Rocket Pharmaceuticals, Inc.
RCKT
$3.47
$0.133.89%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -36.25% | -30.62% | -15.16% | 2.10% | 22.25% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -27.37% | -21.31% | -16.36% | -8.72% | -0.98% |
| Operating Income | 27.37% | 21.31% | 16.36% | 8.72% | 0.98% |
| Income Before Tax | 96.65% | 18.85% | 13.77% | 6.65% | -1.60% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 93.30% | 18.85% | 13.77% | 6.65% | -1.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 93.30% | 18.85% | 13.77% | 6.65% | -1.60% |
| EBIT | 27.37% | 21.31% | 16.36% | 8.72% | 0.98% |
| EBITDA | 28.24% | 22.16% | 17.56% | 9.87% | 1.78% |
| EPS Basic | 93.45% | 28.56% | 26.48% | 18.39% | 10.36% |
| Normalized Basic EPS | 32.75% | 29.54% | 27.42% | 19.25% | 11.56% |
| EPS Diluted | 92.97% | 28.56% | 26.48% | 18.39% | 10.36% |
| Normalized Diluted EPS | 32.99% | 29.54% | 27.42% | 19.25% | 11.56% |
| Average Basic Shares Outstanding | 8.61% | 12.89% | 17.28% | 14.79% | 13.64% |
| Average Diluted Shares Outstanding | 9.01% | 12.89% | 17.28% | 14.79% | 13.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |